20:53 , Oct 12, 2018 |  BC Extra  |  Tools & Techniques

iPS cell-derived models offer new opportunities for drug screening

New models for Down syndrome and amyotrophic lateral sclerosis harness patient-derived induced pluripotent stem (iPS) cells to overcome genetic and cell heterogeneities inherent to the disorders not adequately recapitulated by cell culture and animal models....
18:49 , Jul 13, 2018 |  BioCentury  |  Finance

Curating Abingworth

With a narrower set of investment strategies and a diversified LP base for its latest fund, Abingworth is seeking double digit returns from the $315 million Bioventures VII. Abingworth’s Kurt von Emster told BioCentury the...
19:38 , May 26, 2017 |  BC Extra  |  Clinical News

Team identifies potential target pathway for ALS

In a paper published in...
01:00 , Feb 17, 2017 |  BC Innovations  |  Targets & Mechanisms

Gilding the Goldfinch

In launching Goldfinch Biopharma Inc. , Third Rock is extending its already heavy footprint in precision medicine into chronic kidney disease. The VC thinks the unfolding genetics in that field can yield disease-modifying therapies and...
00:40 , Dec 21, 2016 |  BC Week In Review  |  Clinical News

Bosulif: Ph III BFORE data

Top-line data from the open-label, international Phase III BFORE trial in 536 patients with chronic phase Ph+ CML showed that first-line treatment with once-daily 400 mg oral Bosulif met the primary endpoint of a greater...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Company News

Pfizer sales and marketing update

The U.K.’s NICE issued final guidance recommending the use of Bosulif bosutinib from Pfizer to treat chronic, accelerated and blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults who have been treated with...
07:00 , Aug 2, 2016 |  BC Extra  |  Politics & Policy

CVS reveals changes to 2017 formulary

In a list of updates to its standard formulary for 2017, CVS Health Corp. (NYSE:CVS) said it will remove 35 drugs, including three oral cancer therapies, and will replace some biologics with biosimilars and follow-on...
07:00 , Jul 29, 2016 |  BC Extra  |  Politics & Policy

Cancer Drugs Fund relaunched

The U.K.'s Cancer Drugs Fund (CDF) was relaunched Friday, and is now accepting new drugs for inclusion. In order to better control costs, NHS England and NICE revamped the CDF earlier this year, making it...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Company News

Pfizer sales and marketing update

The U.K.’s NICE issued a final appraisal determination (FAD) recommending the use of Bosulif bosutinib from Pfizer to treat chronic, accelerated and blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults who have...
00:29 , Jul 7, 2016 |  BC Extra  |  Company News

NICE backs Pfizer's Bosulif in first reappraisal of cancer fund drug

The U.K.'s NICE issued a final appraisal determination recommending use of leukemia drug Bosulif bosutinib from Pfizer Inc. (NYSE:PFE). The recommendation is the first reappraisal of a drug that was covered by the U.K.'s Cancer...